

ALLIED HEALTHCARE PRODUCTS INC

Form 8-K

November 09, 2018

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

November 8, 2018

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware **0-19266** **25-1370721**
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

1720 Sublette Avenue, St. Louis, Missouri 63110
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code

(314) 771-2400

Not applicable

(Former name or former address, if changed since last report)

Edgar Filing: ALLIED HEALTHCARE PRODUCTS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 5.07. Submission of Matters to a Vote of Security Holders.

The annual meeting of the stockholders of Allied Healthcare Products, Inc. (the “Company”) was held on November 8, 2018. Proxies were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934. There was no solicitation in opposition to management’s nominees for Directors. The voting results are noted below.

ELECTION OF DIRECTORS

All nominees for Directors were elected with the following votes cast:

	For	Withheld	Broker Non-Votes
Judith T. Graves	2,224,911	76,030	1,279,458
Joseph E. Root	2,227,879	73,062	1,279,458
William A. Peck	2,221,538	79,403	1,279,458
Earl R. Refsland	2,229,011	71,930	1,279,458
John D. Weil	2,227,586	73,085	1,279,458

Agenda Item 2, concerning the ratification of the appointment of RubinBrown LLP as the Company’s independent registered public accounting firm for fiscal 2019 was approved by the stockholders with the following votes cast:

For	Against	Abstain	Broker Non-Votes
3,394,533	179,890	5,975	0

Agenda Item 3, an advisory (non-binding) vote to approve our executive compensation was approved by the stockholders with the following votes cast:

For	Against	Abstain	Broker Non-Votes
2,144,586	136,272	20,084	1,279,458

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALLIED HEALTHCARE
PRODUCTS, INC.

Date: November 9, 2018 By: /s/ Daniel C. Dunn
Daniel C. Dunn
Chief Financial Officer